IPSEN SA S/ADR - IPSEY STOCK NEWS

Ipsen announced that its Phase III NAPOLI 3 trial of Onivyde (irinotecan liposome injection) has successfully met its primary endpoint. The trial demonstrated a statistically significant improvement in overall survival for patients with metastatic pancreatic ductal adenocarcinoma compared to the nab-paclitaxel plus gemcitabine regimen. Key secondary endpoints, including progression-free survival, also showed significant results. Ipsen plans to file a supplemental New Drug Application with the FDA following these promising results.

Ipsen (IPSEY) reported robust sales performance for YTD 2022, with total sales reaching €2,208.5m, marking a 15.5% increase year-over-year, and growth of 9.5% at constant exchange rates (CER). Key drivers included Oncology sales rising by 12.9%, Neuroscience by 31.7%, and total sales in Q3 up 16.0%. However, Rare Disease sales decreased by 9.8%, and Somatuline sales suffered a 2.8% decline due to increased competition. Ipsen confirmed its FY 2022 guidance, expecting total-sales growth greater than 7% at CER. The recent acquisition of Epizyme enhances Ipsen’s Oncology portfolio.

Ipsen (ADR: IPSEY) announces the FDA's postponement of the advisory committee meeting for its investigational drug palovarotene, originally scheduled for October 31, 2022. The FDA seeks additional information regarding clinical trial data but assures that the delay does not relate to the drug's safety profile. Ipsen is collaborating with the FDA to provide the requested data. The company remains committed to developing innovative treatments for Fibrodysplasia Ossificans Progressiva.

The press release from Ipsen outlines key information related to the total number of shares and voting rights as of September 30, 2022. The share capital comprises 83,814,526 shares, resulting in a gross total of 132,099,605 voting rights and a net total of 130,919,539 voting rights. These figures reflect the company's compliance with regulatory requirements under French law. The press release emphasizes the importance of disclosing threshold crossings in accordance with existing statutory clauses.

Ipsen announced its updated share capital details as of August 31, 2022. The total number of shares composing the share capital is 83,814,526. The gross total of voting rights is 132,106,626, while the net total stands at 130,930,000. This report is in accordance with the French Commercial Code and the regulations of the Autorité des Marchés Financiers. The company operates in the Euronext Paris market, with ISIN Code FR 0010259150 and LEI 549300M6SGDPB4Z94P11.

IPSEN has reported aggregated stock transactions on XPAR for the period from 29th August 2022 to 1st September 2022. A total of 7,669 shares were traded, with a daily weighted average price averaging €95.44 across the transactions. The daily volumes varied, with the highest on 31st August recording 2,200 shares at a price of €96.00.

This information serves to inform investors about the recent trading activity of IPSEN stocks.

The press release from Ipsen details the company's stock transactions between August 22 and August 26, 2022. During this period, a total of 10,500 shares were acquired across multiple days with daily volumes of 3,000 on the 22nd, 2,500 on the 23rd, 2,000 on the 24th, and 3,000 on the 26th. The daily average prices per share varied from approximately 95.26 to 97.87 euros, culminating in an overall average price of 96.68 euros for the total shares acquired. These transactions reflect Ipsen's ongoing market activities on the Euronext Paris platform.

The press release from Ipsen reports on stock transactions for August 16-18, 2022. The company bought a total of 4,797 shares over these three days, with daily transactions of 1,697, 2,000, and 1,100 shares respectively. The weighted average prices for these shares were 96.9538, 96.8226, and 96.1234 for each day, culminating in an overall average price of 96.7087. The issuer identification code is 549300M6SGDPB4Z94P11 and the financial instrument ID is FR0010259150. All transactions were conducted on the XPAR platform.

Ipsen has successfully completed the acquisition of Epizyme, Inc., purchasing all outstanding shares for $1.45 per share plus a contingent value right of $1.00 per share. Following this transaction, Epizyme will operate as an Ipsen company. The acquisition includes Epizyme's lead product, Tazverik (tazemetostat), an EZH2 inhibitor, already approved for certain types of lymphoma and sarcoma. Ipsen also gains development candidate EZM0414, a SETD2 inhibitor under Phase I/Ib trials. This strategic move is expected to enhance Ipsen's oncology portfolio and patient reach.